- Pelvital’s seed funding round, led by Boomerang Ventures, has raised $2.68 million for Flyte® development.
- Flyte® is a unique, at-home intravaginal device for treating Stress Urinary Incontinence (SUI) and strengthening pelvic floor muscles.
- The funds will fuel further product development and accelerate the commercialization of Flyte®, making it accessible to more women and clinicians.
- Flyte® has shown to deliver surgical-level results with conservative, fast, and convenient at-home treatment.
Founded in 2023 and based in Eagan, Minnesota, Pelvital is a frontrunner in women’s health. The company’s groundbreaking product, Flyte®, is an FDA-cleared treatment designed to counter Stress Urinary Incontinence (SUI) and fortify weakened pelvic floor muscles. Leveraging the therapeutic power of mechanotherapy, Flyte® is the only at-home intravaginal device of its kind that can swiftly and effectively address this common health concern among women.
Flyte®: A Beacon of Hope for Women’s Health
Conceptualized by physicians from the Arctic University of Norway in cooperation with gynecological and muscle rehabilitation experts, Flyte® is an innovative, non-invasive solution to combat SUI. Mechanotherapy, its principal modality, triggers tissue repair and the creation of neuromuscular memory when combined with an active pelvic floor contraction.
“Pelvital is committed to empowering both women and clinicians with transformative products backed by strong clinical evidence,” said Lydia Zeller, President and CEO of Pelvital. “In the context of significant gaps in health equity – and in particular for issues that disproportionately impact peri-menopausal and menopausal women – increasing access to clinically proven, patient-centric treatments is vitally important.”
Flyte® requires a mere five minutes of daily use over six weeks. It has been proven effective for mild, moderate, and severe SUI and is FDA-cleared for both over-the-counter and prescription use.
The Fundraising Journey
Boomerang Ventures, a venture capital firm specializing in transformative connected health, led the seed funding round. Other investors included VisionTech Partners, Wisconsin Investment Partners, and Edward Bergmark, PhD, Founder, and former CEO of Optum.
Oscar Moralez, Founder, and Managing Partner of Boomerang Ventures, shared his excitement over the successful investment, stating, “Boomerang Ventures is driven to solve the biggest challenges in healthcare which is why we’re so excited about this investment in Flyte by Pelvital. Their commitment to innovation, science-backed results, research and development, and user experience is making a significant impact on lives and on the cost of care. We have understood for a long time both the opportunity and the historic underfunding in women’s health care, and we’re beginning to understand how largely neglected the menopause segment is. We are incredibly proud to be part of the contingent addressing this gap.”
The influx of funds will be deployed towards the completion of Pelvital’s next-generation product and accelerating Flyte®’s commercialization, expanding its reach to a wider audience of women and clinicians seeking an effective, convenient, in-home treatment for SUI.
Two clinical trials assessing the safety, efficacy, and durability of Flyte® in women with SUI have shown encouraging results. Flyte® demonstrates continence rates and durability comparable to surgical interventions but with a more conservative, quick, and convenient treatment approach.
The Future for Pelvital and Flyte®
This successful funding round marks an exciting turning point for Pelvital and the Flyte® product, bringing them a step closer to their vision of becoming the gold standard of care for the treatment of urinary incontinence. As Flyte® continues to gather momentum, it is expected to make a transformative impact on women’s health, addressing an underserved area and leading the way in revolutionizing the treatment of Stress Urinary Incontinence.
With this strategic partnership with Boomerang Ventures and other investors, Pelvital is poised to expand its reach and make its groundbreaking solution available to an even broader audience of clinicians and women seeking an effective, in-home treatment for SUI.